LLY - Eli Lilly and Company
After hours:
| Previous Close | 445.66 |
| Open | 449.30 |
| Bid | 446.51 x 800 |
| Ask | 445.95 x 800 |
| Day's Range | 442.60 - 449.30 |
| 52 Week Range | 283.11 - 454.95 |
| Volume | |
| Avg. Volume | 3,201,171 |
| Market Cap | 423.414B |
| Beta (5Y Monthly) | 0.37 |
| PE Ratio (TTM) | 69.48 |
| EPS (TTM) | 6.42 |
| Earnings Date | Aug 08, 2023 |
| Forward Dividend & Yield | 4.52 (1.04%) |
| Ex-Dividend Date | May 12, 2023 |
| 1y Target Est | 439.78 |
Simply Wall St.We Think Eli Lilly (NYSE:LLY) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
ZacksEli Lilly (LLY) Gains But Lags Market: What You Should Know
In the latest trading session, Eli Lilly (LLY) closed at $446.04, marking a +0.09% move from the previous day.
ZacksBiogen (BIIB), Eisai's Alzheimer Drug Likely to Get Full FDA Nod
Based on briefing documents issued by the FDA, a full regulatory approval is expected on Biogen (BIIB)/Eisai's Alzheimer's disease antibody. The final decision is expected in the early next month.
Motley FoolCould Pfizer Have an Ozempic Killer on the Way?
It wasn't because so many patients were newly diagnosed with type 2 diabetes. Instead, Ozempic gained widespread popularity for helping people lose weight. A sibling product, Wegovy, a higher-dose version of the active ingredient in Ozempic that is actually approved for weight loss, has flown off pharmacies' shelves as well.
- Simply Wall St.
Eli Lilly (NYSE:LLY) jumps 3.9% this week, though earnings growth is still tracking behind five-year shareholder returns
Long term investing can be life changing when you buy and hold the truly great businesses. And we've seen some truly...
- Reuters
UPDATE 1-Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
Novartis breast cancer drug Kisqali cut the risk of recurrence by more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and but facing strong competition from Eli Lilly. The company on Friday said the relative risk reduction of cancer recurrence was 25.2% and that the results were broadly consistent regardless of patients' menopausal status or cancer progression status. The Swiss drugmaker's shares rose, even as the efficacy read-out fell short of that of a drug by Lilly, but a more favourable side effect profile might swing the balance in favour of Kisqali.
ReutersNovartis drug cuts recurrence risk by 25% in early-stage breast cancer
Novartis breast cancer drug Kisqali cut the risk of recurrence by more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and but facing strong competition from Eli Lilly. The company on Friday said the relative risk reduction of cancer recurrence was 25.2% and that the results were broadly consistent regardless of patients' menopausal status or cancer progression status. The results were presented at the annual meeting of the American Society of Clinical Oncology in Chicago.
ZacksEli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
ZacksZacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis
Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.
BloombergObesity Shot Frenzy Makes Eli Lilly World’s Most Valuable Drugmaker
(Bloomberg) -- Eli Lilly & Co.’s third straight month of gains has helped it become the largest pharmaceutical company in the world by market value, surpassing Johnson & Johnson.
Zacks5 Large Drug Stocks to Watch From a Thriving Industry
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.
Motley Fool2 Newly Minted AI Stocks to Buy Right Now
Nowhere is this trend more evident than in the recent parabolic growth of graphics, computing, and networking solutions company Nvidia (NASDAQ: NVDA). Thanks to its central role as a pillar of global AI architecture, Nvidia has seen its market cap swell to nearly $1 trillion in 2023.
Motley FoolBetter Dividend Stock: Eli Lilly or Novo Nordisk?
Dividend stocks, on balance, tend to deliver market-beating returns on capital over the long haul. The key reason is that regular dividend payments amplify returns through the power of compounding. Selecting dividend stocks is no easy task, however.
- Simply Wall St.
Calculating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Eli Lilly fair value estimate is US$373 Current share price of...
- Reuters
UPDATE 1-AbCellera to make C$701 million co-investment in Canada
AbCellera Biologics said on Wednesday it will make a C$701 million ($515.6 million) co-investment with the governments of Canada and British Columbia to strengthen capabilities for drug development, manufacturing and clinical research in the country. Over the next eight years, the company will invest C$401 million in the project, and the governments of Canada and British Columbia will contribute C$225 million and C$75 million, respectively.
ZacksPfizer's (PFE) Oral Diabetes Drug Aids in Weight Loss, Stock Up
Data from a phase II study published in JAMA showed that Pfizer's (PFE) danuglipron reduces glycated hemoglobin and fasting plasma glucose (at all doses) and body weight (at the highest doses) at week 16.
Motley Fool1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market
Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak.
ZacksInvestors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
BloombergDrugmakers Eye $23 Billion Biotech Argenx Ahead of Key Data
(Bloomberg) -- European biotech firm Argenx SE is scheduled to release key drug trial data this summer. Deal-hungry Big Pharma is closely watching.Most Read from BloombergHere’s How Much Wealth You Need to Join the Richest 1% GloballyMercedes Sets Out to Make Sexy Vans With Yacht-Like InteriorsJPMorgan Asset Says Markets Are Right to Bet on US Rate CutsDebt-Limit Talks to Intensify as Biden Set to Depart for JapanSeveral major drugmakers keen to expand in immunology have been studying the $23 bi
- Simply Wall St.
With 84% ownership of the shares, Eli Lilly and Company (NYSE:LLY) is heavily dominated by institutional owners
Key Insights Significantly high institutional ownership implies Eli Lilly's stock price is sensitive to their trading...
ZacksEli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth
Lilly (LLY) expects to launch four new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched.
Motley FoolThese 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win
Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) are both keen to compete in the market for Alzheimer's disease therapies. Biogen's prior attempt at an Alzheimer's medicine to hit the market was a train wreck, but its latest drug seems to be avoiding a repeat. Meanwhile, Eli Lilly has yet to submit its candidate for regulatory review.
Motley Fool3 Growth Stocks to Buy and Hold
The stock market's short-term volatility can sometimes cloud investors' judgment and cause panic selling. In that spirit, we asked three Motley Fool contributors to discuss buy-and-hold-worthy growth stocks. Read on to find out why they picked Axsome Therapeutics (NASDAQ: AXSM), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX).
Motley FoolWill Eli Lilly Be a Trillion-Dollar Stock by 2030?
Most investors are comfortable with the idea of businesses like Apple and Microsoft having market caps in excess of $1 trillion. Today, Eli Lilly's market cap is a little north of $410 billion, which puts it among the top handful of big pharma companies. Its trailing 12-month net income is $6.2 billion, and its trailing price-to-earnings ratio is near 69, which is fairly high, but not at bloated tech stock levels.
- Simply Wall St.
Should We Be Delighted With Eli Lilly and Company's (NYSE:LLY) ROE Of 50%?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
